Home - www.pronexus.se
Search - www.pronexus.se
Home Japan - www.pronexus.se

Company profile

 

The establishment of Pronexus Analytical AB in 2003 was preceded by a long-term scientific collaboration between the company founders, Professors Kjell Fuxe, Urban Ungerstedt and Jan Kehr affiliated at Department of Neuroscience and Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm. Pronexus is a privately owned fully proprietary and independent preclinical contract research organization.

 company leaflet.pdf (Download)

Pronexus offers advanced services and collaborative projects in CNS pharmacology, neurochemistry and tissue metabolism in experimental disease models. Pronexus core expertise covers in vivo techniques for monitoring neurotransmitter release and metabolism, rodent models of CNS disorders, PK/PD studies and testing the implantable medical devices and drug delivery systems. The bioanalytical services include high-sensitive HPLC, UHPLC-MS/MS and UPLC-TOF techniques, as well as, immunoassays and enzymatic assays for determination of neurotransmitters and other neuroactive molecules, metabolites and drug levels in the microdialysis samples, plasma, CSF, cell lysates and brain tissue extracts. Pronexus bioanalytical laboratory and the animal research facility are GLP-compliant with full regulatory approvals.
In addition, Pronexus Analytical AB offers services and instruments for in vivo biosensor technology in partnership with Quanteon LLC, USA. Implantable biosensors allow real time monitoring on second-by-second basis of neurotransmitter release and reuptake in anaesthetized and awake animals, as well as, in brain slices and in combination with electrophysiological recordings.

Personnel

The team of senior scientists (5 of them with PhD degree) at Pronexus Analytical and collaborators at Karolinska Institutet comprise an internationally recognized group in the field of experimental neuropharmacology and neurodegenerative models with focus on microdialysis and neurochemical analysis. Collectively we have more than 100 years of research experience both in academia and industry. We offer interactive communication on daily basis with our clients, flexibility in protocol design required particularly for exploratory studies, method development and collaboration with academia.

Partners

NeuroAssets, Switzerland (www.neuroassets.com)                                                                                              Porsolt, France (www.porsolt.com)                                                                                                                   Quanteon, USA (www.quanteon.cc)

M Dialysis (www.mdialysis.com), CMA Microdialysis (www.microdialysis.se

Microbiotech/se (www.microbiotech.se

U-FOLD - Forum for research on addiction to medical products and illegal drugs, Uppsala University, Sweden (www.ufold.uu.se

Karolinska Institutet Science Park, Stockholm, Sweden (www.ki.se/sciencepark

Stockholm Life (www.stockholm-life.se, Tools of Science, Sweden (www.toolsofscience.se